Kidney, cardiovascular and all-cause mortality outcomes of semaglutide with and without baseline MRA use in type 2 diabetes and CKD: a FLOW trial analysis Meeting Abstract

Industry Collaboration International Collaboration

cited authors

  • Rossing, P.; Bakris, G. L.; Perkovic, V.; Pratley, R.; Tuttle, K.; Mahaffey, K.; Idorn, T.; Nazal, N. B.; Bosch-Traberg, H.; Rasmussen, S.; Busch, R. S.; Schmieder, R.; Gillard, P.; Mann, J.; FLOW Invest Grp

Publication Date

  • September 1, 2024

webpage

published in

category

start page

  • S519

end page

  • S519

volume

  • 67